🔗 Share this article

As the US continues making sweeping adjustments to its vaccination recommendations, one figure has surfaced in a surprising turn: Høeg, a Danish American sports medicine doctor and epidemiologist who initially gained attention by expressing skepticism about COVID-19 shots in the pandemic and has concentrated on possible deaths following Covid vaccination in her short tenure at the Food and Drug Administration.

Scheduled Shifts to Childhood Immunization Schedule

Public health authorities had intended to unveil radical changes to the pediatric vaccination calendar recently, aligning the US with the Danish national calendar, according to reports – a substantial departure that would place the US out of alignment with many the global community with insufficient data for public health gain. The announcement has been postponed until the coming year.

Rather than the top vaccines chief, Høeg is set to present at the gathering. She was just designated acting director of the FDA’s CDER, the fifth person to run the division this year.

Consolidating Power at the FDA

This interim role may indicate a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it points to a increased emphasis upon rolling back long-standing vaccines at the FDA.

Høeg has often pushed for halting some pediatric shot schedules in the US so as to align more in line with the Danish model, a nation with nationalized medicine and a number of inhabitants roughly the population of Wisconsin’s.

To date statements, she has continued to focus on immunizations – usually the responsibility of Dr. Prasad, director of the FDA’s CBER – instead of pharmaceutical oversight.

Concerns Over Background

The appointee has little discernible experience in medication creation, regulation or leadership, which has been typical for previous leaders of the CBER. She has served at the FDA as a top consultant to the commissioner and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for running the pharmaceutical oversight division, said a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She has no expertise in running a major agency. She lacks background in industry regulation.”

Past directors of CBER would “grasp legal statutes and the research of drug development”, noted Janet Woodcock. “Frankly, she doesn’t have the sort of resume that prior appointees who led CBER have had.”

CDER has an immense workload at the agency, Woodcock emphasized.

“The public just focuses on the novel medication approvals, but the generic program clears a multitude of off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and other areas, and every single one need to be supervised,” Dr. Woodcock explained. “The thing you neglect, that is the part that I always told people is going to cause problems.”

There is also, a significant administrative element to the job, which oversees in excess of 5,000 employees. “It’s a enormous administrative position, if you perform it correctly,” Woodcock added.

Response and Controversial Initiatives

When asked about inquiries about Høeg’s fitness for the role and whether this appointment signifies greater collaboration among FDA leaders on vaccines, a spokesperson responded that the “inquiries are based on flawed presumptions”.

“This background aligns with the functions of her role,” the representative stated, noting the period Dr. Høeg spent advising the FDA commissioner on “medication safety and oversight research, including computational safety modeling and immunization monitoring”.

As acting director, Høeg inherits the commissioner’s controversial priority voucher program, a controversial one-day drug-approval program that allegedly troubled her preceding directors. “By what process are these drugs being selected for this expedited pathway? Who is making the choices?” Dr. Howard asked. “There is a lot of secrecy happening at the FDA right now.”

Broadly speaking, he said, “the agency looks to be trending towards more relaxed regulations of all drugs, with the exception of vaccines.”

Public Past Work on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if troubling, track record, some experts observe. She published a research paper using unconfirmed volunteer-provided data to determine the frequency of myocarditis after COVID-19 immunization. She advised the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccines are pose a greater threat than they are.

Part of her “desired changes” for the incoming federal leadership featured revising rules for novel immunizations and discontinuing “optional” vaccines, she remarked following the vote on a online show. At the FDA, Dr. Høeg has according to sources suggested excluding teenage boys from obtaining Covid vaccinations.

“She is an complete dogmatist who commences with her beliefs and tailors the evidence to retrofit the evidence in a very disingenuous, fraudulent way,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with fellow contrarians, {like|